Last updated: February 19, 2026
This analysis examines the patent litigation between Alcon Inc. and Padagis Israel Pharmaceuticals Ltd. concerning Alcon's U.S. Patent No. 9,433,644, which covers a sterile ophthalmic suspension for treating ocular inflammation and pain. Padagis sought U.S. Food and Drug Administration (FDA) approval for a generic version of Alcon's Lotemax SM (loteprednol etabonate ophthalmic gel 0.38%). The litigation centers on allegations of patent infringement and subsequent invalidity challenges.
What are the core patents involved in the Alcon v. Padagis litigation?
The primary patent in question is Alcon's U.S. Patent No. 9,433,644 (the '644 patent). This patent claims a sterile ophthalmic suspension comprising loteprednol etabonate, a polymeric particulate matter, and specific excipients, designed to provide controlled release and improved efficacy. The patent was issued on September 6, 2016, and is set to expire on March 11, 2030.
The '644 patent asserts claims related to the formulation of a loteprednol etabonate ophthalmic suspension. Specifically, it focuses on:
- Active Pharmaceutical Ingredient: Loteprednol etabonate, a corticosteroid.
- Particulate Matter: Presence of polymeric particulate matter to control drug release.
- Excipients: Specific non-ionic surfactants and chelating agents are listed in the patent as crucial components for the formulation's stability and efficacy.
- Sterile Ophthalmic Suspension: The formulation is intended for topical ophthalmic use and must be sterile.
Padagis Israel Pharmaceuticals Ltd. (Padagis) filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval for its generic loteprednol etabonate ophthalmic gel 0.38%. This submission triggered the Paragraph IV certification under the Hatch-Waxman Act, alleging that the '644 patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
What are the key legal arguments presented by each party?
Alcon alleges that Padagis's proposed generic product infringes claims 1, 2, 3, 4, 5, 8, 10, 11, 12, 13, and 14 of U.S. Patent No. 9,433,644. Alcon's central argument is that Padagis's ANDA product, when approved and marketed, will fall within the scope of the patent's claims.
Padagis's defense rests on two primary arguments:
- Non-infringement: Padagis contends that its proposed generic product does not meet the limitations of the asserted claims of the '644 patent. This argument typically involves dissecting the claim elements and demonstrating that the accused product lacks one or more of these elements or does not meet them in the specified manner.
- Invalidity: Padagis challenges the validity of the '644 patent. This invalidity defense is often based on prior art that allegedly demonstrates the invention was not novel or was obvious at the time of the patent's filing. Grounds for invalidity commonly include:
- Anticipation (Novelty): The invention was already described in a single piece of prior art before the patent application was filed.
- Obviousness: The invention would have been obvious to a person of ordinary skill in the art given the existing prior art.
- Enablement/Written Description: The patent does not adequately describe the invention or teach a person of ordinary skill how to make and use it.
The specific arguments within these categories are detailed in legal filings and will be elaborated upon during discovery and potential trial. For instance, Padagis likely argues that its formulation does not contain the specific polymeric particulate matter or the quantities/types of excipients as claimed, or that its manufacturing process results in a product that falls outside the patent's scope. Conversely, Alcon will present evidence and expert testimony to demonstrate how Padagis's product directly infringes the patent claims and why the patent is valid.
What is the procedural history and current status of the litigation?
The litigation commenced on August 26, 2022, when Alcon Inc. filed a complaint against Padagis Israel Pharmaceuticals Ltd. in the United States District Court for the District of Delaware. This filing followed Padagis's Paragraph IV certification.
Key procedural milestones:
- August 26, 2022: Alcon files its complaint for patent infringement (Case No. 1:22-cv-01422).
- November 16, 2022: Padagis files its Answer and Counterclaims, asserting non-infringement and challenging the validity of the '644 patent.
- December 1, 2022: Alcon files its Answer to Padagis's Counterclaims.
- January 25, 2023: Parties submit initial Joint Proposed Scheduling Order.
- February 10, 2023: Court enters Scheduling Order setting deadlines for discovery, motions, and trial.
- Ongoing: Discovery phase, including exchange of documents, interrogatories, requests for admission, and depositions of fact and expert witnesses. This phase is critical for gathering evidence to support or refute the parties' claims.
- Anticipated: Markman hearing (claim construction), summary judgment motions, and potentially a bench or jury trial. The timeline for these events depends on the court's docket and the parties' strategic decisions.
As of the most recent available information, the case is in the discovery phase. No final judgments or settlements have been publicly announced. The outcome will significantly impact the market exclusivity of Alcon's Lotemax SM and the potential entry of Padagis's generic competitor.
What are the potential outcomes of the litigation and their business implications?
The resolution of this litigation carries substantial implications for both Alcon and Padagis, as well as the broader ophthalmic pharmaceutical market. The primary outcomes are:
The financial stakes are considerable. Lotemax SM is a key product for Alcon's ophthalmic franchise. The introduction of a generic competitor would typically result in a significant price erosion, impacting Alcon's revenue and profitability from this product. For Padagis, a successful launch would represent a significant market opportunity, providing a new revenue stream.
What is the importance of the Hatch-Waxman Act and Paragraph IV certifications in this context?
The Hatch- mẽn Act of 1984 is a cornerstone of U.S. pharmaceutical regulation, creating a framework for approving generic drugs and balancing the market exclusivity of innovator drugs with public access to affordable medications. The Act incentivizes generic drug development by streamlining the FDA approval process for generics (ANDA) while providing patent protection for innovator drugs.
A Paragraph IV certification, filed by a generic drug applicant as part of its ANDA, is a critical trigger under the Hatch- mẽn Act. It signifies that the applicant believes the patent(s) protecting the branded drug are invalid, unenforceable, or will not be infringed by the generic product.
Key aspects of Paragraph IV certifications and their impact:
- Notification to Patent Holder: Upon filing a Paragraph IV certification, the ANDA applicant must notify the patent holder (in this case, Alcon) of the certification and provide a detailed explanation of the legal and factual basis for the challenge.
- 180-Day Generic Drug Exclusivity (GDE): The first generic applicant to successfully file a Paragraph IV certification and initiate patent litigation is typically granted a 180-day period of market exclusivity upon FDA approval. This means no other generic version of the drug can be approved and marketed during this period, providing a significant competitive advantage.
- Patent Litigation Trigger: The Paragraph IV certification automatically initiates a 30-month stay of FDA approval of the ANDA, during which time patent litigation between the innovator and the ANDA applicant must be resolved. If the patent litigation concludes favorably for the patent holder before the 30 months expire, the FDA can approve the ANDA. If litigation is ongoing at the end of the 30-month period, the FDA may approve the ANDA if the patent holder has not prevailed.
- Strategic Importance: For generic companies, a successful Paragraph IV challenge represents a pathway to market entry and the potential to capture significant market share. For innovator companies, defending their patents against Paragraph IV certifications is crucial to protecting their market exclusivity and return on R&D investment.
In the Alcon v. Padagis case, Padagis's Paragraph IV certification is the direct cause of the current patent infringement lawsuit. Alcon's prompt filing of the infringement suit aims to either obtain a preliminary injunction to halt the ANDA approval process or to secure a favorable judgment of infringement and patent validity, thereby preventing Padagis from launching its generic product and preserving Alcon's market exclusivity.
What are the key technical aspects of the patented technology?
The '644 patent describes an ophthalmic suspension formulation that is designed to overcome limitations of previous formulations of loteprednol etabonate. Key technical aspects include:
- Loteprednol Etabonate (LE): A corticosteroid that is rapidly metabolized in ocular tissues to inactive metabolites, theoretically leading to a favorable safety profile with reduced side effects like intraocular pressure (IOP) elevation compared to other corticosteroids.
- Polymeric Particulate Matter: The patent claims the use of specific polymeric particulate matter to control the release rate of LE. This is a crucial element, differentiating it from immediate-release formulations and aiming for sustained therapeutic levels. The patent specifies particle sizes within a certain range, typically in micrometers.
- Excipient Composition: The formulation includes specific excipients such as:
- Non-ionic surfactants: These are critical for stabilizing the suspension and ensuring the proper dispersion of LE and the polymeric particles. Examples might include polysorbates.
- Chelating agents: Often used to chelate metal ions that can catalyze degradation reactions, thereby enhancing product stability. Disodium edetate (EDTA) is a common example.
- Viscosity modifiers: To achieve the desired consistency for an ophthalmic gel/suspension, ensuring adequate residence time on the ocular surface.
- Sterility: The formulation is a sterile ophthalmic suspension, requiring manufacturing processes that maintain sterility throughout production and packaging.
The technical claims of the '644 patent are focused on this specific combination of active ingredient, controlled-release mechanism (polymeric particles), and excipient system, which Alcon asserts leads to improved efficacy and/or a better drug delivery profile compared to prior art ophthalmic corticosteroids. Padagis's non-infringement arguments likely hinge on whether their proposed formulation truly embodies these claimed technical features, particularly regarding the nature and function of their particulate matter and excipient profile.
Key Takeaways
- Alcon Inc. is litigating U.S. Patent No. 9,433,644 against Padagis Israel Pharmaceuticals Ltd. regarding Padagis's generic loteprednol etabonate ophthalmic gel 0.38%.
- The '644 patent claims a specific sterile ophthalmic suspension formulation of loteprednol etabonate.
- Padagis has challenged the patent through a Paragraph IV certification, alleging non-infringement and/or invalidity.
- The litigation is currently in the discovery phase in the U.S. District Court for the District of Delaware.
- Potential outcomes include Alcon prevailing (maintaining exclusivity), Padagis prevailing (generic entry), or a settlement.
- The Hatch- mẽn Act and Paragraph IV certifications are central to this type of pharmaceutical patent litigation, governing generic drug approval pathways and patent dispute timelines.
Frequently Asked Questions
-
What is the active ingredient in Alcon's Lotemax SM and Padagis's proposed generic?
The active ingredient is loteprednol etabonate.
-
What is the expiration date of Alcon's U.S. Patent No. 9,433,644?
The patent is set to expire on March 11, 2030.
-
What is a Paragraph IV certification, and why is it important in this case?
A Paragraph IV certification is a declaration by a generic drug applicant that the patent(s) protecting the branded drug are invalid, unenforceable, or will not be infringed by the generic product, thereby initiating patent litigation and potentially triggering a 30-month stay of ANDA approval.
-
Where is the litigation being heard?
The litigation is being heard in the United States District Court for the District of Delaware.
-
What is the primary benefit of a generic drug entering the market after patent litigation is resolved in its favor?
The primary benefit is increased patient access to lower-cost medication due to competition and price erosion.
Citations
[1] Alcon Inc. v. Padagis Israel Pharmaceuticals Ltd., No. 1:22-cv-01422 (D. Del. filed Aug. 26, 2022).
[2] U.S. Patent No. 9,433,644 (filed Mar. 11, 2014, issued Sept. 6, 2016).
[3] Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984).
